PubMed ID:
19458364
Public Release Type:
Journal
Publication Year: 2009
Affiliation: University of Iowa College of Medicine and the Veterans Affairs Medical Center, Iowa City, IA 52242-1081, USA. bradley-dixon@uiowa.edu
DOI:
https://doi.org/10.1056/NEJMoa0805840
Authors:
Martin K,
Schmitz P,
Jenkins V,
Cotton J Jr,
Husband E,
Allon M,
Robbin M,
Lockhart M,
Casey B,
Newsome J,
Dixon B,
Franzwa B,
Hunsicker L,
Hoballah J,
Katz D,
Sharp W,
Kresowik T,
Wu Y,
Rayhill S,
Pflederer T,
DuPage K,
Welch K,
Darras F,
Banqero A,
Ketel B,
Wounded Arrow A,
Grant C,
Deeb J,
Pyszka L,
Slavin M,
Wedeking D,
Vazquez M,
Davidson I,
Toto R,
Littmon L,
Ying C,
Lightfoot T,
Quinones H,
Saxena R,
Clagett P,
Valentine J,
Dolmatch B,
Thompson J,
Fenves A,
Pearl G,
Ikizler A,
Egbert P,
McNeil J,
Holmes D,
Delmez J,
Freiberger W,
Dixon BS,
Beck GJ,
Vazquez MA,
Greenberg A,
Delmez JA,
Allon M,
Dember LM,
Himmelfarb J,
Gassman JJ,
Greene T,
Radeva MK,
Davidson IJ,
Ikizler TA,
Braden GL,
Fenves AZ,
Kaufman JS,
Cotton JR Jr,
Martin KJ,
McNeil JW,
Rahman A,
Lawson JH,
Whiting JF,
Hu B,
Meyers CM,
Kusek JW,
Feldman HI,
DAC Study Group,
Dember L,
Windus D,
Coyne D,
Rothstein M,
Shenoy S,
Creaghan R,
Lluka B,
Kusek J,
Stehman-Breen C,
McClellan W,
Louis T,
Diener-West M,
Chertow G,
Besarab A,
Levin N,
Weiss B,
Tuason L,
Radeva M,
Liu A,
Bi S,
Hu B,
Greene T,
Gassman J,
Beck G,
Feldman H,
Meyers C,
Kaufman J,
Hawley M,
Lauer A,
LeSage P,
Nathan R,
Holmberg E,
Braden G,
Ryan M,
Berkowitz A,
Rahman A,
Lucas B Jr,
Santos R,
Reyes B,
Greenberg A,
Berkoben M,
Kovalik E,
Lawson J,
Middleton J,
Schwab S,
Schumm D,
Adams S,
Gitter K,
Cantaffa T,
Quarles A,
Work J,
Rhodes S,
Himmelfarb J,
Whiting J,
Kane J,
Freedman S,
Violette R,
Cyr-Alves H,
Garrison K
Studies:
Dialysis Access Consortium
,
Dialysis Access Consortium GRAFT
Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity.